A study identifying predictors impacting the use rivaroxaban versus low molecular weight heparin for cancer-associated thrombosis in patients with ovarian cancer
Latest Information Update: 12 Jul 2021
At a glance
- Drugs Low molecular weight heparins (Primary) ; Rivaroxaban (Primary)
- Indications Pulmonary embolism; Thrombosis
- Focus Therapeutic Use
- 12 Jul 2021 New trial record
- 08 Jun 2021 Results evaluating the effectiveness and safety of rivaroxaban versus low molecular-weight heparin (LMWH) for cancer-associated thrombosis (CAT) treatment in patients with ovarian cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology